Common adverse effects included neutropenia, nausea, constipation, and fatigue, while hyperbilirubinemia was observed in 14% of patients and IDH inhibitor-associated differentiation syndrome (IDH-DS) was observed in 16% of patients; however, the overall adverse effects were manageable, and no treatment-related deaths occurred. Here, IDH1 is linked to Dravet syndrome.